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Abstract
Tetanus is an illness that is still prevalent although the
incidence has markedly decreased largely due to immunisation
programmes. The latest four cases managed at St. Luke’s
hospital over 2001-2002 are presented. All of these patients
survived. We give an overview of the illness and discuss the cases
and management. The potential benefit of using dual antibiotic
therapy is questioned.
Introduction
The incidence of tetanus has been decreasing in the
developed world mainly due to effective immunisation
programmes. As a result, physicians are less exposed to the
features of this serious, potentially fatal illness. However,
sporadic cases serve to raise awareness that although this
disease has been largely overcome mainly through preventative
methods, it is still around and an index of suspicion has to be
maintained in patients presenting with the characteristic
features. Here we describe four cases to demonstrate the
features and management issues that may arise in these cases.
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Case 1
LA, a previously healthy 63-year-old male, was referred with
an inability to swallow liquids and solids, followed by a 24 hr
history of inability to open and close his mouth. Symptoms
started insidiously and progressed slowly.  He had a history of
a traumatic nail puncture wound in the right foot 19 days prior
to presentation. He had been treated at a health centre and was
given anti-tetanus toxoid (ATT) and antibiotics.  The patient
stopped his antibiotics after 5 days of treatment. On
examination, a small wound in the right foot, 5cm in diameter
and 2-3cm deep, was present. He had neck stiffness and trismus
of the jaw.  There was no evidence of cardiovascular or
respiratory failure.  A diagnosis of tetanus was made and he
was admitted to the Intensive Care Unit (ICU) and treated with
benzyl penicillin and metronidazole. He also received
antitetanus immunoglobulin (ATIG), his wound was debrided
and he was placed on a magnesium sulphate infusion.  After 4
days on ICU, the patient had to be ventilated because of
progressive respiratory failure and subsequently required a
tracheostomy. His stay on ICU was largely uneventful apart from
supra-infection with multiresistant Stephylococcus aureus
(MRSA). After 29 days the muscle relaxants were stopped. He
was transferred to the Infectious Disease Unit (IDU) after 33
days and discharged home on day 37.
Case 2
HB, an 82 year old well preserved male with a history of
asthma, adenocarcinoma prostate and nephrectomy due to
pyonephrosis, presented with a 3 day history of difficulty
opening mouth which initially started after an argument with
his wife. He was seen by a dental surgeon and later by an Ear,
Nose and Throat (ENT) surgeon and eventually admitted to the
ENT ward. He had a history of an injury to the right popliteal
fossa 1 week before. On being seen by the Infectious Disease
team, he had lockjaw, was cyanosed and had basilar creps. He
had no focal neurological signs. A clinical diagnosis of tetanus
was made and he received ATIG 10,000 U, intravenous benzyl
penicillin and metronidazole. Since he was in respiratory failure
from pulmonary oedema, he was immediately intubated and
ventilated. In intensive care, he was treated with the above
antibiotics as well as inotropes and a magnesium infusion.
Complications included nosocomial infections which were
treated, supraventricular tachycardia and limb oedema.
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Episodic spasms were controlled with adjustment of sedation
and magnesium infusion. After 39 days on intensive care, he
was transferred to the IDU from where he was discharged home.
Case 3
CP, a 66-year-old male hypertensive was seen at ENT
Accident and Emergency (A&E) Department complaining of a
3 day history of difficulty in opening his mouth, and 1 day history
of problems with swallowing. 1 week before he had injured his
left big toe while gardening with subsequent avulsion of his
toenail. On examination, the patient had trismus, jaw opening
was limited to 1cm, and lateral jaw movements were limited.
The left big toenail had been avulsed but there was no
surrounding cellulitis. He had last taken Anti tetanus toxoid
about 20 years before. He was admitted to the IDU and started
on benzyl penicillin and metronidazole intravenously. ATT cover
was given and later antitetanus immunoglobulin. The day after
admission he was feeling worse with increasing difficulty with
opening his mouth and swallowing, choking on oral fluids and
difficulty moving his tongue, talking and keeping his eyes open.
He was transferred to intensive care and observed but 2 days
later developed respiratory distress and was ventilated, sedated
and muscle relaxed.  During this time he was being treated with
the above antibiotics, and magnesium infusion. He was also
treated for nosocomial pneumonia. After 40 days he was
transferred from Intensive Care back to the IDU where he was
discharged well and independent a few days after.
Case 4
RG, a 76 year old lady was referred from A&E to ENT for
assessment of a 7 day history of difficulty swallowing. On
examination, she had limited tongue movements and facial
features suggestive of trismus, together with an inability to open
the mouth fully. Flexible laryngoscopy showed a normal larynx.
Some swelling of the face was present and superior vena cava
(SVC) obstruction was initially entertained. She had a history
of walking in her fields with some minor abrasions on her legs.
An SVC venogram was however negative. She was started on
co-amoxiclav and hydrocortisone and an Infectious Disease
consultation asked for. The picture was not any clearer and a
spatula test done and was negative repeatedly. The antibiotic
spectrum was broadened and metronidazole added. Within the
next two days, the situation was slightly worse, and the patient
was also complaining of back pain, but no spasm. A clinical
diagnosis of tetanus was made and the patient transferred to
the ICU. She was given ATIG and benzyl penicillin was added.
She was started on a magnesium infusion and her superficial
wounds debrided. She managed to maintain the airway and the
spasm in her mouth got better. Swallowing improved and she
was transferred to the IDU after seven days, where she was
gradually weaned off magnesium. On day 18 in hospital, her
antibiotics were stopped and she was discharged home to
continue a course of ATT.
Up to the time of this submission, two further cases were
being managed at St Luke’s Hospital and were doing well out of
intensive care after prolonged supportive measures including
mechanical ventilation in the ICU.
Overview
The first description of tetanus dates back to 460-377 BC
by Hippocrates and Egyptian physicians. It was well known to
ancient civilisations who recognised the relationship of injury
to fatal spasms. The name derives from the Greek Tetanos, to
stretch.
 Carle and Rattone first produced tetanus in animals by
injecting them with pus from a fatal human tetanus case in 1884.
During the same year, Nicolaier produced tetanus in animals
by injecting them with samples of soil. In 1889, Kitasato reported
that the toxin could be neutralized by specific antibodies. In
1897, Nocard demonstrated the protective effect of passively
transferred antitoxin, and passive immunization in humans was
used during World War I. Tetanus toxoid was developed by
Descombey in 1924, and the effectiveness of active
immunization was demonstrated in World War II. Many of the
immunisation programmes started after this time.
Aetiology
This illness is caused by an exotoxin called Tetanospasmin,
produced by Clostridium tetani, anaerobic gram-positive rods
which can form spores with the characteristic drumstick
appearance. Spores are found in soil, dust, and animal faeces,
and may persist for months to years. They are very resistant to
environmental extremes and chemical agents. Clostridium
tetani spores enter the body, usually via an open wound, the
spores germinate, and toxins, including tetanospasmin, are
produced, and disseminated via blood and lymphatics.
Pathophysiology
Tetanospasmin binds to receptors via pre-synaptic terminals
of the lower motor neurone resulting in local failure of
neuromuscular transmission. It travels up the axon to the cell
body and diffuses to terminals of inhibitory cells, preventing
transmitter release. It thus leaves motor neurons without
inhibition and leads to unopposed muscle contraction and
spasm. This may also result in seizures and autonomic nervous
system dysfunction.
Clinical features
The incubation period varies between 3-21 days, averaging
8 days. Four types of clinical presentations can occur:
generalised, local, cephalic and neonatal tetanus. Generalised
tetanus is the most common form and usually starts with spasm
of the masseter muscle. Neck rigidity, dysphagia and facial
muscle involvement are also early features, the latter causing
the risus sardonicus. Progression occurs into generalised muscle
spasms and tonic contractions, which can even cause fractures,
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tendon ruptures and respiratory failure. Local tetanus presents
with persistent muscle spasm in the muscles close to the injury.
Patients with cephalic tetanus have cranial nerve palsies and
this can follow head trauma or otitis media. Neonatal tetanus
occurs in underdeveloped countries after contamination of the
umbilical cord after delivery.
Differential diagnosis
The condition which may mimic tetanus is strychnine
poisoning. Other conditions, which may cause trismus, include
dental infections (note the second patient was referred to
dentistry initially), encephalitis, local neoplasms and hysteria.
Muscle dystonic reactions secondary to neuroleptics may also
cause neck stiffness, but this usually includes lateral head
turning which is rare in tetanus.
Epidemiology
In the year 2000, only 18 833 cases of tetanus were reported
to the World Health Organization worldwide1, but there was
lack of data from many countries which are at greatest risk from
this disease.2   In Malta the annual reported number of cases of
tetanus has been decreasing since the late 1970’s (Figure 1). The
figure of around 8 cases per year declined to about 1 case per
year over the past 7 years (no cases in1999). In 2003, however,
there was an increase in trend with 3 cases being diagnosed.
Current statistics indicate that the mortality rate varies from
6% to 60%, depending on severity. A shorter incubation period
is associated with increased mortality, as is age more than 60
years.
Diagnosis
The diagnosis is made on a clinical basis. A bedside clinical
test, called the spatula test can be used: this involves touching
the oropharynx with a spatula which usually elicits a gag reflex
and repulsion. The test is positive when the patient develops a
reflex spasm of the masseters and bites the spatula. This test is
said to have a 94% sensitivity and 100% specificity, and no
adverse sequelae from this test have been reported.
Laboratory studies help to exclude other conditions.
Strychnine levels in serum and urine help exclude toxicity. CSF
studies are usually not necessary but would help to differentiate
encephalitis. Although a serum tetanus antibody level
of >0.01 U/ml is commonly cited as ‘protective’, there have been
many case reports of disease in patients with antibody levels
above this.3
 C. tetani may be recovered from the wound in only 30% of
cases. However, this can also be isolated from patients who do
not have tetanus. Laboratory identification of the organism
depends most importantly on the demonstration of toxin
production in injected mice.
Management
Principles of management include support of the airway and
control of spasms initially. This is done by ventilation, if
necessary, in an intensive care setting, and use of antispasmodic
agents. The initial agents of choice would be the
benzodiazepines, particularly diazepam or lorazepam. Other
agents, which may be used, include midazolam, propofol, and
intrathecal baclofen.  Several studies have also demonstrated
the benefit of magnesium infusion as an antispasmodic agent.4
This agent is especially important in resource poor areas,
averting the need for mechanical ventilation.5  If control cannot
be achieved by these agents, then neuromuscular junction
blockade and ventilation will be necessary, whilst still
maintaining an adequate dose of sedation.
Possible antibiotic treatments of tetanus include
metronidazole and benzyl penicillin. Morbidity is less with
metronidazole than with benzyl penicillin.6  This is because
benzyl penicillin is a GABA antagonist, which may decrease the
spasm threshold. Alternative antibiotics include doxycycline and
carbapenems. Activity against the organism is also
demonstrated by macrolides and cephalosporins.
Tetanus immune globulin should be given in the first
instance to remove unbound tetanus toxin. It does not affect
toxin bound to nerve endings. Tetanus disease does not result
in tetanus immunity because of the extreme potency of the toxin,
and active immunization with tetanus toxoid should begin when
the patient’s condition improves, before discharge from hospital.
Sympathetic over activity is a major cause of tetanus-related
death in the intensive care unit and is usually treated with
labetalol. Beta blockade alone may result in unopposed alpha-
adrenergic activity resulting in severe hypertension. Other
complications that commonly arise include nosocomial
infections and pulmonary embolism.
Discussion
The cases described above bear similarities in presentation
and management. All presented with difficulty in using the
oropharyngeal musculature. Indeed 50-75% of patients with
tetanus present with trismus. It seems the tendency is for them
to be referred to the ENT department for assessment, and the
likelihood is that they will be diagnosed here. Alternatively they
Figure 1: Annual number of reported cases of Tetanus:
Malta 1978-2003
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may present to the dental surgeons. It is therefore important
for practitioners in both these specialities to retain a high index
of suspicion for this disease.
Although there is a definite differential diagnosis, the most
similar presentation being strychnine poisoning, physicians with
experience in this illness should not find major difficulty in
arriving at a diagnosis and initiating treatment. Strychnine levels
should be taken, but institution of treatment cannot wait for
the results of this test. In cases of doubt, referral to the Infectious
Disease team should be done.
The spatula test was used in Case 4, but was negative, ie.
the patient rejected the spatula when this was introduced into
the mouth. This is a normal reflex. In tetanus, the test turns
positive, and the patient bites on the spatula because of reflex
spasm of the masseters.  This test was 94% sensitive and 100%
specific in a study involving 400 patients.7
All four were treated with dual antibiotic treatment initially.
Metronidazole was found to be better tolerated than benzyl
penicillin in one clinical study. However the benefit of
administering both antibiotics together is not known. A
literature search did not reveal any studies looking for survival
advantage with this regimen. All four patients survived but the
benefit, if any, that dual antibiotic treatment had on the outcome
cannot be determined.  Studies have shown an association of
increased mortality with increasing age. In our case, all four
patients were above 60 years of age. The mortality in
unvaccinated individuals in the United States is 15%.
All patients spent between 30-40 days on intensive care.
They were all treated with a magnesium sulphate infusion in
line with current trends . In our context, it was not used as a
substitute to ventilation, but as an antispasmodic in conjunction
with ventilation. However, in Case 4, ventilation was avoided
altogether, probably with the help of magnesium sulphate. Our
experience showed that it is well tolerated and a useful adjunct
to benzodiazepines.
The incidence of tetanus in Malta has decreased since the
late 1970’s.  This is probably due to better uptake of
immunisation since this was made mandatory. Also, increased
awareness of the disease could have led to better tetanus
prophylaxis administered at the primary level for at risk injuries.
A similar decline has been observed in other countries such as
the United States where the number of cases has fallen from
0.5/100,000 in 1947 to 0.02/100,000 in 1990.8   The rise in
cases in Malta during 2003 cannot currently be explained.
Clearly the key to overcome this disease lies in prophylaxis.
Tetanus is a preventable disease and there should be no excuse
as to why people are not immunised against it. Moreover, when
wounds at risk occur, they should be thoroughly cleaned and
dead or devitalized tissue removed. Further management of the
patient is outlined in the Guidelines seen in Table 1, depending
on the type of wound sustained (Table 2). Administration of
prophylactic antibiotics should be considered if the
immunisation history is unknown or if less than 3 doses of ATT
have been given ever.   However, the importance of proper
immunisation of patients with wounds at risk cannot be
overemphasised.
Conclusion
Tetanus is an illness that has been largely overcome in Malta,
but a very low level of incidence is still present. This is probably
due to an effective immunisation programme, as well as proper
management of tetanus prone wounds. The potential benefit of
dual antibiotic treatment with benzyl penicillin and
metronidazole may warrant further study.
Table 1: Guidelines on Tetanus wound management8
Immunisation History Clean, non-tetanus prone wounds Dirty, tetanus prone wounds
ATT ATIG ATT ATIG
Unknown or < 3 doses ever Yes No Yes Yes
3 or more doses ever No* No No** No
*   Yes if >10 years since last dose;  ** Yes if > 5 years since last dose
Table 2: Wound classification9
Clinical Features Tetanus prone Non-tetanus prone
Age of wound >6 hours <6 hours
Depth Stellate, >1cm <1cm
Mechanism of injury Missile, crush, burn, frostbite Sharp surface (glass, knife)
Contamination Present Absent
Devitalised tissue Present Absent
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PharmaNews
Simvastatin reduces the risk of stroke
The largest-ever study using a cholesterol-modifying
medication, simvastatin, (Zocor®, MSD), demonstrated a
highly significant reduction in the incidence of stroke and
other major vascular event by 25% and 24%, respectively, in
patients who had coronary heart or other occlusive arterial
disease or diabetes.  This benefit was seen regardless of
baseline cholesterol, age or gender compared with placebo.
In this study, reported in the Lancet, patients received 40 mg
simvastatin once daily.
Eprosartan reduces future risk
in hypertensive stroke patients
The antihypertensive eprosartan (Teveten®, Solvay) has
now been shown to offer effective protection against
cerebrovascular and cardiovascular events in hypertensive
patients with a previous stroke, over and above that offered
by blood pressure reduction alone. The MOSES study has
shown that BP was equally well controlled in hypertensive
patients with a history of stroke with eprosartan or
nitrendipine.  However, in patients treated with eprosartan
there was a significant reduction of 20% in mortality and
cardio/cerebrovascular events, 25% reduction in the
recurrence of stroke, TIAs and reversible neurological deficit,
and 30% in first-time cardiovascular events.
Valsartan reduces the incidence
of diabetes in high-risk patients
The recently published VALUE study (The Lancet)
showed that valsartan (Diovan®, Novartis Pharma),
compared with amlodipine, was associated with a reduction
of 23% in new-onset diabetes in 15,245 hypertensive patients
at risk of cardiovascular complications. This study
highlighted the need for both aggressive BP lowering and
cardiac and metabolic protective regimens in this ‘at risk’
patient population.
Letrozole reduces risk
of breast cancer recurrence
The MA-17 study (New England Journal of Medicine)
has shown that extended adjuvant treatment with letrozole
(Femara ®, Novartis Pharma) cut the risk of relapse by 42%
in post-menopausal women with hormone receptor positive
or unknown early breast cancer who have received standard
adjuvant tamoxifen therapy for five years. Letrozole has
obtained ‘fast track’ approval for use following tamoxifen
therapy in post-menopausal women with early breast cancer.
Pimecrolimus offers relief for paediatric
and adult eczema sufferers
Pimecrolimus 1% (Elidel®, Novartis Pharma) has been
proven to control the acute signs and symptoms of eczema,
and reduces the incidence of flares. A non-steroidal cream,
pimercrolimus is safe to be used all over the body including
the face, neck and delicate skin areas, is well-tolerated and
eliminates the need for corticosteroids, improves long-term
disease control and enhances the patients’ quality of life.
